ScholarIQanswers from OpenAlex & ORCID
Nina Bhardwaj
ResearcherPublications, citations & collaboration network
Nina Bhardwaj is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nina Bhardwaj have?
ScholarIQindexed works
Nina Bhardwaj has 773 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nina Bhardwaj have?
ScholarIQcitation count
Nina Bhardwaj has 45,520 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nina Bhardwaj?
ScholarIQh-index
Nina Bhardwaj has an h-index of 104 in OpenAlex.
What is the i10-index of Nina Bhardwaj?
ScholarIQi10-index
Nina Bhardwaj has an i10-index of 285 in OpenAlex.
What is the ORCID of Nina Bhardwaj?
ScholarIQorcid
The ORCID for Nina Bhardwaj is on the source record.
What is the OpenAlex record for Nina Bhardwaj?
ScholarIQopenalex
The OpenAlex for Nina Bhardwaj is on the source record.
What are the most-cited papers on Nina Bhardwaj?
ScholarIQmost cited works
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Kevin C. Barry, Joy Hsu, Miranda L. Broz, Francisco J. Cueto, Mikhail Binnewies, Alexis J. Combes, Amanda E. Nelson, Kimberly Loo, Raj Kumar, Michael D. Rosenblum, Michael Alvarado, Denise M. Wolf, Dusan Bogunovic, Nina Bhardwaj, Adil Daud, Patrick K. Ha, William R. Ryan, Joshua L. Pollack, Bushra Samad, Saurabh Asthana, Vincent Chan, Matthew F. Krummel
A conserved dendritic-cell regulatory program limits antitumour immunity
Bárbara Maier, Andrew M. Leader, Steven T. Chen, Navpreet Tung, Christie Chang, Jessica LeBérichel, Aleksey Chudnovskiy, Shrisha Maskey, Laura Walker, John P. Finnigan, Margaret E. Kirkling, Boris Reizis, Sourav Ghosh, Natalie Roy D’Amore, Nina Bhardwaj, Carla V. Rothlin, Andrea Wolf, Raja M. Flores, Thomas U. Marron, Adeeb Rahman, Ephraim Kenigsberg, Brian D. Brown, Miriam Mérad
TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer
Matthew D. Park, Ivan Reyes-Torres, Jessica LeBérichel, Pauline Hamon, Nelson M. LaMarche, Samarth Hegde, Meriem Belabed, Leanna Troncoso, John A. Grout, Assaf Magen, Étienne Humblin, Achuth Sankar S. Nair, Martina Molgora, Jinchao Hou, Jenna H. Newman, Adam M. Farkas, Andrew M. Leader, Travis Dawson, Darwin D’souza, Steven Hamel, Alfonso R. Sánchez-Paulete, Bárbara Maier, Nina Bhardwaj, J.P. Martin, Alice O. Kamphorst, Ephraim Kenigsberg, María Casanova-Acebes, Amir Horowitz, Brian D. Brown, Lucas Ferrari de Andrade, Marco Colonna, Thomas U. Marron, Miriam Mérad
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial
Thomas U. Marron, Maria Isabel Fiel, Pauline Hamon, Nathalie Fiaschi, Edward Kim, Stephen C. Ward, Zhen Zhao, Joel Kim, Paul Kennedy, Ganesh Gunasekaran, Parissa Tabrizian, Deborah B. Doroshow, Meredith Legg, Ashley Hammad, Assaf Magen, Alice O. Kamphorst, Muhammed Shareef, Namita Gupta, Raquel P. Deering, Wei Wang, Fang Wang, Pradeep Thanigaimani, Jayakumar Mani, Leanna Troncoso, Alexandra Tabachnikova, Christie Chang, Güray Aktürk, Mark Buckup, Steven Hamel, Giorgio Ioannou, C. Hennequin, Hajra Jamal, Haley E. Brown, Antoinette Bonaccorso, Daniel M. Labow, Umut Sarpel, Talia D. Rosenbloom, Max W. Sung, Baijun Kou, Siyu Li, Vladimir Janković, Nicola James, Sara Hamon, Hung Kam Cheung, Jennifer S. Sims, Elizabeth Miller, Nina Bhardwaj, Gavin Thurston, Israel Lowy, Sacha Gnjatic, Bachir Taouli, Myron Schwartz, Miriam Mérad
Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer
Sylvia Adams, Lina Kozhaya, Frank Martiniuk, Tze‐Chiang Meng, Luis Chiriboga, Leonard Liebes, Tsivia Hochman, Nicholas S. Shuman, Deborah Axelrod, James L. Speyer, Yelena Novik, Amy Tiersten, Judith D. Goldberg, Silvia C. Formenti, Nina Bhardwaj, Derya Unutmaz, Sandra Demaria